Literature DB >> 21165620

Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care.

Michelle C Ellis1, Brian S Diggs, John T Vetto, Daniel O Herzig.   

Abstract

BACKGROUND: New medical therapies available to ulcerative colitis (UC) patients have influenced operative mortality for patients requiring colectomy. We sought to examine trends in treatment and outcome for UC patients treated surgically.
METHODS: A review of 36,447 UC patients from the Nationwide Inpatient Sample was performed, comparing the pre-monoclonal antibody era (1990-1996) to the present-day era (2000-2006). Patients treated with total colectomy with ileostomy or proctocolectomy with ileal pouch were reviewed for outcome measures and practice setting (rural, urban non-teaching, urban teaching). Our main outcome measures were in-hospital mortality, length of stay, and total charges.
RESULTS: Total colectomy (n = 30,362) was performed five times more often than proctocolectomy (n = 6,085). When comparing the two study periods, mortality after total colectomy increased 3.8% to 4.6% (p = 0.0003). This difference was primarily due to increasing mortality in later years; when 1995-1996 was compared to 2005-2006, mortality increased from 3.6% to 5.6% (p < 0.0001). There were no deaths in the proctocolectomy group (p < 0.0001). The distribution by practice setting shifted over the two study periods, decreasing in rural (7.0% to 4.8%) and urban non-teaching (43.7% to 28.4%) centers, and increasing in urban teaching centers (49.3% to 66.8%). The total inflation-adjusted charges per patient increased significantly ($34,638 vs. $43,621; p < 0.0001).
CONCLUSIONS: The mortality rate after total colectomy is increasing, and the difference is accentuated in the years since widespread use of monoclonal antibody therapy. The care of these patients is being shifted to urban teaching centers and is becoming more expensive.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21165620     DOI: 10.1007/s00268-010-0910-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Course of ulcerative colitis: analysis of changes in disease activity over years.

Authors:  E Langholz; P Munkholm; M Davidsen; V Binder
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

Review 2.  Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.

Authors:  M M Lawson; A G Thomas; A K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

3.  Trends in hospitalization rates for inflammatory bowel disease in the United States.

Authors:  Meenakshi Bewtra; Chinyu Su; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-26       Impact factor: 11.382

4.  Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study.

Authors:  Charles N Bernstein; Alice Nabalamba
Journal:  Am J Gastroenterol       Date:  2006-01       Impact factor: 10.864

5.  Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Authors:  William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2009-07-28       Impact factor: 22.682

6.  Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.

Authors:  Chelliah R Selvasekar; Robert R Cima; David W Larson; Eric J Dozois; Jeffrey R Harrington; William S Harmsen; Edward V Loftus; William J Sandborn; Bruce G Wolff; John H Pemberton
Journal:  J Am Coll Surg       Date:  2007-05       Impact factor: 6.113

7.  Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Authors:  A Aratari; C Papi; V Clemente; A Moretti; R Luchetti; M Koch; L Capurso; R Caprilli
Journal:  Dig Liver Dis       Date:  2008-05-09       Impact factor: 4.088

8.  Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England.

Authors:  E A Russo; A W Harris; S Campbell; J Lindsay; A Hart; N Arebi; A Milestone; H H Tsai; J Walters; M Carpani; D Westaby; A Thillainayagam; D Bansi; S Ghosh
Journal:  Aliment Pharmacol Ther       Date:  2008-11-13       Impact factor: 8.171

9.  Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?

Authors:  Stefanie J Schluender; Andrew Ippoliti; Marla Dubinsky; Eric A Vasiliauskas; Konstantinos A Papadakis; Ling Mei; Stephan R Targan; Phillip R Fleshner
Journal:  Dis Colon Rectum       Date:  2007-11       Impact factor: 4.585

10.  Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery.

Authors:  Liliana Bordeianou; Hiroko Kunitake; Paul Shellito; Richard Hodin
Journal:  Int J Colorectal Dis       Date:  2009-10-02       Impact factor: 2.571

View more
  7 in total

Review 1.  Bridging the gap from T to K: integrated surgical research fellowship for the next generation of surgical scientists.

Authors:  Hunter B Moore; Ernest E Moore; Mark R Nehler; Lisa C Cicutto; Anthony W Bacon; Claire Travis; Richard D Schulick
Journal:  J Am Coll Surg       Date:  2013-11-12       Impact factor: 6.113

Review 2.  Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis.

Authors:  Christopher Alexakis; Richard Cg Pollok
Journal:  World J Gastrointest Surg       Date:  2015-12-27

3.  Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis.

Authors:  Flávia Gonçalves Musauer Palacio; Lucila Marieta Perrotta de Souza; Jéssica Pronestino de Lima Moreira; Ronir Raggio Luiz; Heitor Siffert Pereira de Souza; Cyrla Zaltman
Journal:  BMC Gastroenterol       Date:  2021-04-27       Impact factor: 3.067

4.  Differences and their contexts between teaching and nonteaching hospitals in Iran with other countries: A concurrent mixed-methods study.

Authors:  Niusha Shahidi Sadeghi; Mohammadreza Maleki; Hassan Abolghasem Gorji; Soudabeh Vatankhah; Bahram Mohaghegh
Journal:  J Educ Health Promot       Date:  2022-01-31

Review 5.  The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference?

Authors:  Vivek Chhaya; Richard Pollok
Journal:  F1000Prime Rep       Date:  2013-11-01

6.  Population-based cohort study comparing 30- and 90-day institutional mortality rates after colorectal surgery.

Authors:  B E Byrne; R Mamidanna; C A Vincent; O Faiz
Journal:  Br J Surg       Date:  2013-12       Impact factor: 6.939

Review 7.  Occult and Manifest Colorectal Carcinoma in Ulcerative Colitis: How Does It Influence Surgical Decision Making?

Authors:  Julia Hardt; Peter Kienle
Journal:  Viszeralmedizin       Date:  2015-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.